AUTHORS
Yotam Bronstein, M.D, Libi Feigin, M.D2, Yael C. Cohen, MD3, Svetlana Trestman, MD4, Yakir Moshe, MD, PhD5, Chava Perry, MD, PhD6, Irit Avivi Mazza, MD7
AFFILIATIONS
2 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
3 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
4 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
5 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
6 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
ABSTRACT
Background:
Patients with hematologic malignancies require continuous access to intensive treatment, hematopoietic stem-cell transplantation (HSCT), cellular therapy, clinical trials, and supportive care. However, evidence regarding the maintenance of specialized hematology services during armed conflict remains limited. We evaluated whether a predefined hematology-specific emergency preparedness plan, could preserve the delivery of time-sensitive care during sustained emergency conditions.
Methods:
We conducted a retrospective, single-center comparative cohort study at a tertiary academic medical center, comparing all hematology activity during a 40-day emergency period in 2026 with that of the corresponding calendar period in 2025.
Prior to the conflict, the hospital leadership and the hematology division jointly developed a comprehensive deployment plan. The plan defined the relocation and protected operation of inpatient, outpatient clinic, and day-care services; established patient prioritization and triage processes, including consolidation of visits and treatments, and set out virtual follow-up pathways, communication procedures, infection-control monitoring, and supportive services.
Preparatory multidisciplinary meetings were conducted to establish workflows and ensure operational readiness. Outcomes included clinic, day-care, and inpatient activity; HSCT and chimeric antigen receptor T-cell (CAR-T) therapy; clinical-trial enrollment; microbiological surveillance; hospital length of stay and mortality.
Results:
Upon declaration of the emergency, the predefined plan was activated as designed. Within three hours, Inpatient services were relocated to protected double-occupancy rooms, reducing capacity by 31.0%, from 29 to 20 beds. Clinic activity continued in its original location using protected access pathways and nearby shelters, whereas day-care activity was transferred to a partially protected area with immediate access to shelter. Pre-visit triage, fast-track pathways, visit and treatment consolidation and virtual follow-up were implemented according to the preparedness plan.
Hospitalizations decreased from 89 to 67 (−24.7%), closely paralleling the reduction in available beds. Clinic encounters decreased from 3,296 to 2,585 (−21.6%). By contrast, day-care activity was largely preserved: encounters decreased from 2,087 to 1,795 (−14.0%), while the number of individual day-care patients decreased only from 882 to 843 (−4.4%). Patient demographics and disease distributions were comparable between the two periods, with lymphoproliferative diseases accounting for the majority of hemato-oncologic patients receiving active treatment. Clinical-trial enrollment was maintained, with 25 patients enrolled during the routine period and 24 during the emergency period. CAR-T activity was fully preserved, with 7 infusions performed in each period. Allogeneic HSCT activity was also largely maintained, with 5 procedures during the routine period and 3 during the emergency period, although total HSCT volume decreased from 9 to 4. Among hospitalized patients, weekly screening for vancomycin-resistant Enterococcus and carbapenem-resistant Enterobacterales was maintained, with no newly acquired colonization identified. Median hospital length of stay did not differ significantly between periods (5.04 vs 4.67 days; P=.40). Thirty-day mortality was also similar (7.9% vs 6.0%; risk ratio, 0.76; 95% CI, 0.23–2.49; P=.76).
Conclusions:
A predefined and rapidly activated hematology-specific emergency preparedness plan preserved access to time-sensitive hematologic care despite a substantial reduction in inpatient capacity. Planned relocation to protected facilities, prioritization of ambulatory treatment, maintenance of CAR-T therapy and clinical-trial access, coordinated communication, and rigorous infection-control measures enabled the continuity of advanced hematology services without evidence of worse short-term clinical outcomes. This model provides a practical framework for hematology preparedness during armed conflict and other major healthcare disruptions.
DISCLOSURES
Irit Avivi Mazza, MD: Takeda - Honoraria; Medison - Honoraria; Novartis - Honoraria; AbbVie Inc. - Honoraria; MSD - Honoraria; Gilead - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); MSD - Consultancy (Includes expert testimony); PhenoTA - Consultancy (Includes expert testimony)